Compare iShares MSCI Australia ETF (EWA) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Nuwellis Inc — how do they compare? iShares MSCI Australia ETF trades at $28.27 (market cap $1.19B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: iShares MSCI Australia ETF is far larger — about 540.9× Nuwellis Inc's market cap, and iShares MSCI Australia ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 63 Days and Nuwellis Inc for 26 Days on average.
| EWA | NUWE | |
|---|---|---|
Market Cap | $1.19B | $2.20M |
Volume | 2,714,198 | 121,544 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $146.65 |
52-Week Low | $24.95 | $0.68 |
Typical Hold Time | 63 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Australia ETF (EWA) trades at $28.23, down 1.12% amid bearish technical signals and mixed institutional activity. Recent news highlights Australia's stock market hitting three-month lows due to inflation concerns from rising oil prices, though some analysts see upside potential given the country's commodity-driven economy. Technical indicators show selling pressure with moving averages signaling bearish momentum while oscillators remain neutral.
EWA faces near-term headwinds from Australian market volatility and inflation worries, but long-term prospects remain tied to global commodity demand. The ETF's commodity exposure provides diversification benefits, though investors should monitor Australian economic conditions and Federal Reserve policy impacts. Risk-reward appears balanced with technical resistance at $29 and support at $28.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
